KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization (2016 - 2025)

Regeneron Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $543.7 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 53.54% year-over-year to $543.7 million; the TTM value through Dec 2025 reached $543.7 million, up 53.54%, while the annual FY2025 figure was $543.7 million, 53.54% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $543.7 million at Regeneron Pharmaceuticals, up from $354.1 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $543.7 million in Q4 2025 and troughed at $281.1 million in Q4 2021.
  • A 5-year average of $362.3 million and a median of $328.8 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 7.69% in 2024 and later surged 53.54% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $281.1 million in 2021, then increased by 8.11% to $303.9 million in 2022, then increased by 8.19% to $328.8 million in 2023, then grew by 7.69% to $354.1 million in 2024, then skyrocketed by 53.54% to $543.7 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for REGN at $543.7 million in Q4 2025, $354.1 million in Q4 2024, and $328.8 million in Q4 2023.